Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
AffiliationClinical and Experimental Immunotherapy Group, School of Cancer and Enabling Sciences, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.
MetadataShow full item record
AbstractThe adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a relatively new but promising approach in the field of cancer immunotherapy. This therapeutic strategy is based on the genetic reprogramming of T cells with an artificial immune receptor that redirects them against targets on malignant cells and enables their destruction by exerting T cell effector functions. There has been an explosion of interest in the use of CAR T cells as an immunotherapy for cancer. In the pre-clinical setting, there has been a considerable focus upon optimizing the structural and signaling potency of the CAR while advances in bio-processing technology now mean that the clinical testing of these gene-modified T cells has become a reality. This review will summarize the concept of CAR-based immunotherapy and recent clinical trial activity and will further discuss some of the likely future challenges facing CAR-modified T cell therapies.
CitationTargeted immunotherapy of cancer with CAR T cells: achievements and challenges. 2012, 61 (7):953-62 Cancer Immunol Immunother
JournalCancer Immunology Immunotherapy
- Establishing guidelines for CAR-T cells: challenges and considerations.
- Authors: Wang W, Qin DY, Zhang BL, Wei W, Wang YS, Wei YQ
- Issue date: 2016 Apr
- Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.
- Authors: Shirasu N, Kuroki M
- Issue date: 2012 Jun
- Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.
- Authors: Curran KJ, Pegram HJ, Brentjens RJ
- Issue date: 2012 Jun
- Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges.
- Authors: Han EQ, Li XL, Wang CR, Li TF, Han SY
- Issue date: 2013 Jul 8
- Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
- Authors: Shen CJ, Yang YX, Han EQ, Cao N, Wang YF, Wang Y, Zhao YY, Zhao LM, Cui J, Gupta P, Wong AJ, Han SY
- Issue date: 2013 May 9